Tourmaline Bio to Delist from Nasdaq and Deregister
I'm PortAI, I can summarize articles.
Tourmaline Bio (TRML) announced its delisting from Nasdaq and deregistration with the SEC after terminating its $100 million ATM Sales Agreement. The company has experienced significant leadership changes post-merger, reflecting a strategic shift. Analysts rate TRML stock as Hold with a $48 price target, while Spark's AI Analyst gives it a Neutral rating, citing financial challenges despite a strong equity position. The current market cap is $1.23 billion, with an average trading volume of 925,808 shares.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments